Non-bleeding Peptic Ulcer
Conditions
Brief summary
The aim of the study is to evaluate the safety and efficacy of diosmin as adjuvant therapy in treatment of non-bleeding peptic ulcer patients.
Interventions
DRUGDiosmin
diosmin 500 mg twice daily
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
-. Age 25-65 years old. * Patients of both gender (male and female). * Non-bleeding Peptic ulcer Patients (duodenal &gastric) diagnosed by endoscopy.
Exclusion criteria
* The presence of other factors that can lead to gastric bleeding other than peptic ulcer. * Patients with cancerous disease * Breast-feeding. * Surgically altered stomach ( bariatric surgery), * Patient with liver disease. * Bleeding & perforated peptic ulcer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| assesment of improvement of symptoms as indicated by change in SAGIS scale. | 2 months | patients will undergo clinical assessment according to SAGIS scale at baseline and 2 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in Malondialdehyde (MDA) serum levels. | 2 months | blood samples will be collected at baseline and 2 months. |
| change in Prostaglandin E2 (PGE2) serum levels. | 2 months. | blood samples will be collected at baseline and 2 months. |
| change in Endothelin-1 (ET-1) serum levels. | 2 months | blood samples will be collected at baseline and 2 months. |
| change in b-cell lymphoma 2(bcl-2) serum levels. | 2 months | blood samples will be collected at baseline and 2 months. |
Countries
Egypt
Contacts
Primary ContactAhmed G Abdelfatah
Outcome results
None listed